**9. References**


Fig. 7. Freeze-and-dormancy therapy of malignant tumors by NK4/malignostatin. NK4 blocks tumor invasion and metastasis through an inhibition of HGF-MET signals as an HGF-antagonist. Furthermore, NK4 inhibits tumor angiogenesis via a perlecan-dependent mechanism. Such a dual function of NK4 contributes to "freeze" and "dormancy" anti-

The publication of this manuscript was supported by grants from the Ministry of Education, Science, Technology, Sports and Culture of Japan (the 21st Century global COE program to TN). We would like to thank all co-workers for the continuous studies on the roles of HGF and NK4 during cancer progression. We are also grateful to James L. McDonald (Scientific

Benvenuti, S. & Comoglio, P. M. (2007). The MET receptor tyrosine kinase in invasion and

Beppu, K.; Uchiyama, A.; Morisaki, T.; Matsumoto, K.; Nakamura, T.; Tanaka, M. & Katano,

metastasis. *Journal of Cellular Physiol*ogy, Vol.213, No.2, (November 2009), pp. 316-

M. (2001). Hepatocyte growth factor production by peripheral blood mononuclear

cancer therapy.

**9. References** 

325, ISSN 0021-9541

**8. Acknowledgement** 

Editorial Services; Harrison, AR) for language assistance.

cells of recurrent cancer patients. *Anticancer Research*, Vol.21, No.3C, (May-June 2001), pp. 2195-2200, ISSN 0250-7005.


Endocrine Delivery System of NK4, an HGF-Antagonist and

2000), pp. 245-254, ISSN 0167-6806

1999), pp. 319-329, ISSN 0021-9541

35-69, ISSN 1040-8428

(August 2002), pp. 700-707, ISSN 0929-1903

Anti-Angiogenic Regulator, for Inhibitions of Tumor Growth, Invasion and Metastasis 137

Hirao, S.; Yamada, Y.; Koyama, F.; Fujimoto, H.; Takahama, Y.; Ueno, M.; Kamada, K.;

Jiang, W. G.; Martin, T. A.; Matsumoto, K.; Nakamura, T. & Mansel, R. E. (1999a).

Jiang, W. G.; Hiscox, S. E.; Parr, C.; Martin, T. A.; Matsumoto, K.; Nakamura, T. & Mansel, R.

Jiang, Y.; Xu, W.; Lu, J.; He, F. & Yang, X. (2001). Invasiveness of hepatocellular carcinoma

Jiang, W. G.; Martin, T. A.; Parr, C.; Davies, G.; Matsumoto, K. & Nakamura, T. (2005).

Kajiya, K.; Hirakawa, S.; Ma, B.; Drinnenberg, I. & Detmar, M. (2005). Hepatocyte growth

Kanayama, S.; Yamada, Y.; Kawaguchi, R.; Tsuji, Y.; Haruta, S. & Kobayashi, H. (2008).

Kimura, T.; Sakisaka, T.; Baba, T.; Yamada, T. & Takai Y. (2006). Involvement of the Ras-Ras-

*Chemistry*, Vol.281, No.15, (April 2006), pp. 10598-10609, ISSN 0021-9258 Kishi, Y.; Kuba, K.; Nakamura, T.; Wen, J.; Suzuki, Y.; Mizuno, S.; Nukiwa, T.; Matsumoto,

*Cancer Science*, Vol.100, No.7, (July 2009) pp. 1351-1358, ISSN 1347-9032 Kuba, K.; Matsumoto, K.; Date, K.; Shimura, H.; Tanaka, M. & Nakamura, T. (2000)

*Res*earch, Vol.60, No.23, (December 2000), pp. 6737-6743, ISSN 0008-5472 Kubota, T.; Taiyoh, H.; Matsumura, A.; Murayama, Y.; Ichikawa, D.; Okamoto, K.; Fujiwara,

Vol.5, No.11, (November 1999), pp. 3695-3703, ISSN 1078-0432

(September, 2001), pp. 1123-1130, ISSN 0006-291X

No.16, (August 2005), pp. 2885-2895, ISSN 0261-4189

Vol.19, No.1, (January 2008), pp. 117-122, ISSN 1021-335X

HGF/SF variant, NK4. *Breast Cancer Research and Treatment*, Vol.59, No.3, (February

Mizuno, T.; Maemondo, M.; Nukiwa, T.; Matsumoto, K.; Nakamura, T. & Nakajima, Y. (2002). Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. *Cancer Gene Therapy*, Vol.9, No.8,

Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. *Journal of Cellular Physiology*, Vol.181, No.2, (November

E. (1999b) Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. *Clinical Cancer Research*,

cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. *Biochemical and Biophysical Research Communications*, Vol.286, No.5,

Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. *Critical Reviews in Oncology/Hematology*, Vol.53, No.1, (January 2005), pp.

factor promotes lymphatic vessel formation and function. *EMBO Journal*, Vol.24,

Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. *Oncology Reports*,

activated Rab5 guanine nucleotide exchange factor RIN2-Rab5 pathway in the hepatocyte growth factor-induced endocytosis of E-cadherin. *Journal of Biological* 

K. & Nakamura, T. (2009). Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models.

HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. *Cancer* 

H.; Ikoma, H.; Nakanishi, M.; Kikuchi, S.; Sakakura, C.; Ochiai, T.; Kokuba, Y.; Taniguchi, H.; Sonoyama, T.; Matsumoto, K.; Nakamura, T. & Otsuji. E. (2009a). NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by

kinase oncogenes. *Nature.* Vol.318, No.6044, (November-December 1985), pp. 385- 388, ISSN 0028-0836


Du, W.; Hattori, Y.; Yamada, T.; Matsumoto, K.; Nakamura, T.; Sagawa, M.; Otsuki, T.;

Eder, J. P.; Vande Woude, G. F.; Boerner, S. A. & LoRusso, P. M. (2009). Novel therapeutic

Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman,

*Cancer*, Vol.127, No.12, (December 2010), pp. 2893-2917, ISSN 0020-7136 Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos,

Franco, M.; Muratori, C.; Corso, S.; Tenaglia, E.; Bertotti, A.; Capparuccia, L.; Trusolino, L.;

Geiger, T. R. & Peeper, D. S. (2009). Metastasis mechanisms. *Biochimica et Biophysica Acta*,

Grugan, K. D.; Miller, C. G.; Yao, Y.; Michaylira, C. Z.; Ohashi, S.; Klein-Szanto, A. J.; Diehl,

Hasina, R.; Matsumoto, K.; Matsumoto-Taniura, N.; Kato, I.; Sakuda, M. & Nakamura, T.

Higuchi, O.; Mizuno, K.; Vande Woude, G. F. & Nakamura, T. (1992). Expression of c-met

Hiscox, S. & Jiang, W. G. (1999). Hepatocyte growth factor/scatter factor disrupts epithelial

Hiscox, S.; Parr, C.; Nakamura, T.; Matsumoto, K.; Mansel, R. E. & Jiang, W. G. (2000).

No.1A, (January February, 1999), pp. 509-517, ISSN 0250-7005.

Vol.285, No.50, (December 2010), pp. 38756-38764, ISSN 0021-9258

Vol.1796, No.2, (August 2009), pp. 293-308, ISSN 0006-3002

No.11, (August 1999), pp. 1708-1717, ISSN 0007-0920

2010), pp. 11026-11031, ISSN 0027-8424

No.7, (April 2009), pp. 2207-2214, ISSN 1078-0432

388, ISSN 0028-0836

3049, ISSN 0006-4971

463-475, ISSN 0092-8674

ISSN 0014-5793

kinase oncogenes. *Nature.* Vol.318, No.6044, (November-December 1985), pp. 385-

Niikura, T.; Nukiwa, T. & Ikeda, Y. (2007). NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. *Blood*, Vol.109, No.7, (April 2007), pp. 3042-

inhibitors of the c-Met signaling pathway in cancer. *Clinical Cancer Research*, Vol.15,

N.; Gale, C. M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C. & Jänne, P. A. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*, Vol.316, No.5827, (May 2007), pp. 1039-1043, ISSN 0036-8075 Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C. & Parkin, D. M. (2010). Estimates of

worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of* 

E.; Liesenborghs, L.; Koch, M.; De Mol, M.; Autiero, M.; Wyns, S.; Plaisance, S.; Moons, L.; van Rooijen, N.; Giacca, M.; Stassen, J. M.; Dewerchin, M.; Collen, D. & Carmeliet, P. (2007). Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. *Cell*, Vol.131, No.3, (November 2007), pp.

Comoglio, P. M. & Tamagnone, L. (2010). The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. *Journal of Biological Chemistry,* 

J. A.; Herlyn, M.; Han, M.; Nakagawa, H. & Rustgi, A. K. (2010). Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. *Proceeding of National Academy of Sciences*, Vol.107, No.24, (June

(1999). Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. *British Journal of Cancer*, Vol.80,

proto-oncogene in COS cells induces the signal transducing high-affinity receptor for hepatocyte growth factor. *FEBS Letter*, Vol.301, No.3, (April 1999), pp. 282-286,

tumour cell-cell adhesion: involvement of beta-catenin. *Anticancer Research*, Vol.19,

Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the

HGF/SF variant, NK4. *Breast Cancer Research and Treatment*, Vol.59, No.3, (February 2000), pp. 245-254, ISSN 0167-6806


Endocrine Delivery System of NK4, an HGF-Antagonist and

(July 2005), pp. 316-327, ISSN 0006-291X

2001), pp. 1064-1069, ISSN 0090-4295

327, ISSN 1347-9032

ISSN 1093-9946

0250-7005

1474-175X

0304-3835

ISSN 0006-291X

No.2, (September 1999), pp. 194-202, ISSN 0007-0920

No.3, (August, 2006), pp. 477-483, ISSN 0020-7136

No.16, (August 2008), pp. 3360-3370, ISSN 1615-9861

No.1, (January 2003), pp. 115-123, ISSN 0012-186X

Vol.66, No.7, (April 2006), pp. 3699-3705, ISSN 0008-5472

Anti-Angiogenic Regulator, for Inhibitions of Tumor Growth, Invasion and Metastasis 139

Matsumoto-Taniura, N.; Matsumoto, K. & Nakamura, T. (1999). Prostaglandin production in

Matsumoto, K. & Nakamura, T. (2003). NK4 (HGF-antagonist/angiogenesis inhibitor) in

Matsumoto, K. & Nakamura, T. (2005). Mechanisms and significance of bifunctional NK4 in

Matsumoto, K. & Nakamura, T. (2006). Hepatocyte growth factor and the Met system as a

Matsumoto, K. & Nakamura, T. (2008a). NK4 gene therapy targeting HGF-Met and

Matsumoto, K.; Nakamura, T.; Sakai, K. & Nakamura, T. (2008b). Hepatocyte growth factor

Matsumoto, G.; Omi, Y.; Lee, U.; Kubota, E. & Tabata, Y. (2011). NK4 gene therapy

Miura, H.; Nishimura, K.; Tsujimura, A.; Matsumiya, K.; Matsumoto, K.; Nakamura, T. &

Mueller, M. M. & Fusenig, N. E. (2004). Friends or foes - bipolar effects of the tumour stroma

Nakabayashi, M.; Morishita, R.; Nakagami, H.; Kuba, K.; Matsumoto, K.; Nakamura, T.;

Nagakawa, O.; Murakami, K.; Yamaura, T.; Fujiuchi, Y.; Murata, J.; Fuse, H. & Saiki, I.

Nakaigawa, N.; Yao, M.; Baba, M.; Kato, S.; Kishida, T.; Hattori, K.; Nagashima. Y. &

Nakamura, T.; Nawa, K. & Ichihara, A. (1984). Partial purification and characterization of

mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts. *British Journal of Cancer*, Vol.81,

cancer biology and therapeutics. *Cancer Science*, Vol.94, No.4, (April 2003), pp. 321-

cancer treatment. *Biochemical and Biophysical Research Communications*, Vol.333, No.2,

mediator of tumor-stromal interactions. *International Journal of Cancer*, Vol.119,

angiogenesis. *Frontiers in Bioscience*, Vol.13, No.1, (January 2008), pp. 1943-1951,

and Met in tumor biology and therapeutic approach with NK4. *Proteomics*, Vol.8,

combined with cisplatin inhibits tumour growth and metastasis of squamous cell carcinoma. *Anticancer Research*, Vol.31, No.1, (January 2011), pp. 105-111, ISSN

Okuyama, A. (2001). Effects of hepatocyte growth factor on E-cadherin-mediated cell-cell adhesion in DU145 prostate cancer cells. *Urology*, Vol.58, No.6, (December

in cancer. *Nature Reviews Cancer*, Vol.4, No.11, (November 2004), pp. 839-849, ISSN

Tano, Y. & Kaneda, Y. (2003). HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. *Diabetologia*, Vol.46,

(2000). Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. *Cancer Letter*, Vol.155, No.2, (July 2000), pp. 173-179, ISSN

Kubota, Y. (2006). Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. *Cancer Research*,

hepatocyte growth factor from serum of hepatectomized rats. *Biochemical and Biophysical Research Communications*, Vol.122, No.3, (August 1984), pp. 1450-1459,

inhibiting adhesion of CT26 cells to endothelial cells. *Clinical and Experimental Metastasis*, Vol.26, No.5, (May 2009), pp. 447-456, ISSN 0262-0898


Kubota, T.; Taiyoh, H.; Matsumura, A.; Murayama, Y.; Ichikawa, D.; Okamoto, K.; Fujiwara,

Konishi, T.; Takehara, T.; Tsuji, T.; Ohsato, K.; Matsumoto, K. & Nakamura, T. (1991). Scatter

Laterra, J.; Nam, M.; Rosen, E.; Rao, J. S.; Lamszus, K.; Goldberg, I. D. & Johnston, P. (1997).

Lengyel, E.; Sawada, K. & Salgia, R. (2007). Tyrosine kinase mutations in human cancer. *Current Molecular Medicine,* Vol.7, No.1, (February 2007), pp. 77-84, ISSN 1566-5240 Li, H.; Shimura, H.; Aoki, Y.; Date, K.; Matsumoto, K.; Nakamura, T. & Tanaka, M. (1998).

Maehara, N.; Matsumoto, K.; Kuba, K.; Mizumoto, K.; Tanaka, M. & Nakamura, T. (2001).

Matsumoto, K.; Tajima, H.; Okazaki, H. & Nakamura, T. (1992). Negative regulation of

Matsumoto, K.; Date, K.; Shimura, H. & Nakamura, T. (1996a). Acquisition of invasive

Matsumoto, K.; Date, K.; Ohmichi, H. & Nakamura, T. (1996b). Hepatocyte growth factor in

Matsumoto, K.; Kataoka, H.; Date, K. & Nakamura, T. (1998). Cooperative interaction

*Research*, Vol.87, No.7, (July 1996), pp. 702-710, ISSN 0910-5050

Vol.38 (Supplement), pp. S42-S47, ISSN 0344-5704

*Metastasis*, Vol.26, No.5, (May 2009), pp. 447-456, ISSN 0262-0898

No.12, (December 2009), pp. 2879-2886, ISSN 0020-7136

(October, 1991), pp. 765-773, ISSN 0006-291X

577, ISSN 0023-6837

74-82, ISSN 0262-0898

873, ISSN 0007-0920

31813, ISSN 0021-9258

22913-22920, ISSN 0021-9258

inhibiting adhesion of CT26 cells to endothelial cells. *Clinical and Experimental* 

H.; Ikoma, H.; Nakanishi, M.; Kikuchi, S.; Ochiai, T.; Sakakura, C.; Kokuba, Y.; Sonoyama, T.; Suzuki, Y.; Matsumoto, K.; Nakamura, T. & Otsuji, E. (2009b). Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation. *International Journal of Cancer*, Vol.125,

factor from human embryonic lung fibroblasts is probably identical to hepatocyte growth factor. *Biochemical and Biophysical Research Communications*, Vol.180, No.2,

Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. *Laboratory Investigation*, Vol.76, No.4, (April 1997), pp. 565-

Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. *Clinical and Experimental Metastasis*, Vol.16, No.1, (January 1998), pp.

NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. *British Journal of Cancer*, Vol.84, No.6, (March 2001), pp. 864-

hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta1 and glucocorticoids. *Journal of Biological Chemistry*, Vol.267, No.35, (December 1992), pp. 24917-24920, ISSN 0021-9258 Matsumoto, K.; Matsumoto, K.; Nakamura, T. & Kramer. R. H. (1994). Hepatocyte growth

factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. *Journal of Biological Chemistry*, Vol.269, No.50, (December 1994), pp. 31807-

phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor. *Japanese Journal of Cancer* 

lung morphogenesis and tumor invasion: role as a mediator in epitheliummesenchyme and tumor-stroma interactions. *Cancer Chemotherapy and Pharmacology*,

between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. *Journal of Biological Chemistry*, Vol.273, No.36, (September 1998), pp.


Endocrine Delivery System of NK4, an HGF-Antagonist and

2000), pp. 563-570, ISSN 0020-7136

ISSN 0006-291X

ISSN 0009-7322

22491-22499, ISSN 0021-9258

Anti-Angiogenic Regulator, for Inhibitions of Tumor Growth, Invasion and Metastasis 141

Parr, C.; Hiscox, S.; Nakamura, T.; Matsumoto, K. & Jiang, W. G. (2000). NK4, a new

Parr, C.; Davies, G.; Nakamura, T.; Matsumoto, K.; Mason, M. D. & Jiang, W. G. (2001). The

Pao, W. & Girard, N. (2011). New driver mutations in non-small-cell lung cancer. *The Lancet Oncology*, Vol.12, No.2, (February 2011), pp. 175-180, ISSN 1470-2045 Qian, L. W.; Mizumoto, K.; Inadome, N.; Nagai, E.; Sato, N.; Matsumoto, K.; Nakamura, T. &

*Journal of Cancer*, Vol.104, No.5, (May 2003), pp. 542-549, ISSN 0020-7136 Royal, I.; Lamarche-Vane, N.; Lamorte, L.; Kaibuchi, K. & Park, M. (2000). Activation of

*Biology of the Cell*, Vol.11, No.5, (May 2000), pp. 1709-1725, ISSN 1059-1524 Rubin, J. S.; Bottaro, D. P. & Aaronson, S. A. (1993). Hepatocyte growth factor/scatter factor

Saito, Y.; Nakagami, H.; Morishita, R.; Takami, Y.; Kikuchi, Y.; Hayashi, H.; Nishikawa, T.;

Sakai, K.; Nakamura, T.; Matsumoto, K. & Nakamura, T. (2009). Angioinhibitory action of

Suda, T, & Liu, D. (2007). Hydrodynamic gene delivery: its principles and applications. *Molecular Therapy,* Vol.15, No.12, (December 2007), pp. 2063-2069, ISSN 1525-0016 Tomioka, D.; Maehara, N.; Kuba, K.; Mizumoto, K.; Tanaka, M.; Matsumoto, K. &

Underiner, T. L.; Herbertz, T. & Miknyoczki, S. J. (2010) Discovery of small molecule c-Met

*Medicinal Chemistry*, Vol.10, No.1, (January 2010), pp. 7-27, ISSN 1871-5206 Wader, K.; Fagerli, U.; Holt, R.; Børset, M.; Sundan, A. & Waage, A. (2011). Soluble c-Met in

Wang, R.; Zhang, J.; Chen, S.; Lu, M.; Luo, X.; Yao, S.; Liu, S.; Qin, Y. & Chen, H. (2011)

lung cancer invasion and progression. *Lung Cancer*, in press, ISSN 0169-5002

Vol.1155, No.3, (December 1993), pp. 357-371, ISSN 0006-3002

Vol.61, No.20, (October 2001), pp. 7518-7524, ISSN 0008-5472

*Journal of Haematology*, in press, ISSN 0902-4441

HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. *International Journal of Cancer*, Vol.85, No.4, (February

HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. *Biochemical and Biophysical Research Communications*, Vol.285, No.5, (August 2010), pp. 1330-1337,

Tanaka, M. (2003). Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. *International* 

cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. *Molecular* 

and its receptor, the c-met proto-oncogene product. *Biochimica et Biophysica Acta*,

Tamai, K.; Azuma, N.; Sasajima, T. & Kaneda, Y. (2006). Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. *Circulation*, Vol.114, No.11, (September 2006), pp. 1177-1184,

NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. *Journal of Biological Chemistry,* Vol.284, No.33, (August 2009), pp.

Nakamura, T. (2001). Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. *Cancer Research*,

inhibitors: Evolution and profiles of clinical candidates. *Anti-Cancer Agents in* 

serum of multiple myeloma patients: correlation with clinical parameters. *European* 

Tumor-associated macrophages provide a suitable microenvironment for non-small


Nakamura, T.; Nishizawa, T.; Hagiya, M.; Seki, T.; Shimonishi, M.; Sugimura, A.; Tashiro, K. &

Nakamura, T.; Matsumoto, K.; Kiritoshi, A.; Tano, Y. & Nakamura, T. (1997) Induction of

Nakamura, T.; Sakai, K.; Nakamura, T. & Matsumoto, K. (2010). Anti-cancer approach with

Nakamura, Y.; Morishita, R.; Higaki, J.; Kida, I.; Aoki, M.; Moriguchi, A.; Yamada, K.;

*Hypertension*, Vol.14, No.9, (September 1996), pp. 1067-1072, ISSN 0263-6352 Ohuchida, K.; Mizumoto, K.; Murakami, M.; Qian, L. W.; Sato, N.; Nagai, E.; Matsumoto, K.;

Okamoto, W.; Okamoto, I.; Tanaka, K.; Hatashita, E.; Yamada, Y.; Kuwata, K.; Yamaguchi,

Okunishi, K.; Dohi, M.; Nakagome, K.; Tanaka, R.; Mizuno, S.; Matsumoto, K.; Miyazaki, J.;

*Immunology*, Vol.175, No.7, (October 2005), pp. 4745-4753, ISSN 0022-1767 Olumi, A. F.; Grossfeld, G. D.; Hayward, S. W.; Carroll, P. R.; Tlsty, T.D. & Cunha, G. R.

Osada, S.; Kanematsu, M.; Imai, H. & Goshima, S. (2008). Clinical significance of serum HGF

Pai, R.; Nakamura, T.; Moon, W. S. & Tarnawski, A. S. (2003). Prostaglandins promote colon

*Research*, Vol.64, No.9, (May 2004), pp. 3215-3222, ISSN 0008-5472

2010), pp. 2785-92, ISSN 1535-7163

5002-5011, ISSN 0008-5472

0892-6638

2008), pp. 544-549, ISSN 0172-6390

*Research*, Vol.57, No.15, (August 1997), pp. 3305-3313, ISSN 0008-5472 Nakamura, T. & Mizuno, S. (2010). The discovery of hepatocyte growth factor (HGF) and its

*Factor Research,* Vol.3, No.1. pp. 67-85, ISSN: 0955-2235

Vol.10, No.1, (January 2010), pp. 36-46, ISSN 1871-5206

Shimizu, S. (1989). Molecular cloning and expression of human hepatocyte growth factor. *Nature*, Vol.342, No.6248, (November 1989), pp. 440-443, ISSN 0028-0836 Nakamura, T. (1991). Structure and function of hepatocyte growth factor. *Progress in Growth* 

hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. *Cancer* 

significance for cell biology, life sciences and clinical medicine. *Proceedings of the Japan Academy Series B*, Vol.86, No.6, (June 2010), pp. 588-610 (2010), ISSN 0386-2208

NK4: Bivalent action and mechanisms. *Anti-Cancer Agents in Medicinal Chemistry,* 

Hayashi, S.; Yo, Y.; Nakano, H.; Matsumoto, K.; Nakamura, T. & Ogihara, T. (1996). Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. *Journal of* 

Nakamura, T. & Tanaka, M. (2004) Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. *Cancer* 

H.; Arao, T.; Nishio, K.; Fukuoka, M.; Jänne, P. A. & Nakagawa, K. (2010). TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. *Molecular Cancer Therapeutics,* 2010 Oct; Vol.9, No.10, (Octorber

Nakamura, T. & Yamamoto, K. (2005) A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. *The Journal of* 

(1999). Carcinoma associated fibroblasts direct tumor progression of initiated human prostatic epithelium. *Cancer Research*, Vol.59, No.19, (October 1999), pp.

and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. *Hepatogastroenterology*, Vol.55, No.82-83, (March-April

cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. *FASEB Journal*, Vol.17, No.12, (September 2003), pp. 1640-1647, ISSN


**Part 3** 

**Detailed Experimental** 

**Analyses of Fluids and Flows** 

